Drug firm Granules India on Wednesday said that US health regulator has issued Establishment Inspection Report (EIR) for its Chantilly facility in Virginia, USA.
"This facility was inspected by US Food and Drug Administration (US FDA) in December 2017 and there was one observation during the introspection", it said in a regulatory filing.
The company has responded to the observation in a stipulated timeframe, it further said.
Granules India stock was trading at Rs 118.75 on the BSE, up 1.28% after the announcement.
"This facility was inspected by US Food and Drug Administration (US FDA) in December 2017 and there was one observation during the introspection", it said in a regulatory filing.
The company has responded to the observation in a stipulated timeframe, it further said.
Granules India stock was trading at Rs 118.75 on the BSE, up 1.28% after the announcement.